STAT Plus: Amgen’s KRAS-blocking cancer drug shows durable responses, with tempered expectations

New data from a clinical trial of sotorasib represent “real progress” for lung cancer patients but “expectations should be a bit tempered" given the better partial response rate seen previously.

Click to view original post